BCL6

BCL6

A gene on chromosome 3q27 that encodes a zinc finger transcription factor that acts as a sequence-specific repressor of transcription. BCL6 modulates the transcription of START-dependent IL-4 responses of B cells, and interacts with various POZ-containing transcription co-repressors.

Molecular pathology
BCL6 is often translocated (e.g., t(3;14)(q27;q32); t(3;22)(q27;q11)) and hypermutated in diffuse large-cell lymphoma (DLCL), and may be involved in DLCL pathogenesis.
Mentioned in ?
References in periodicals archive ?
Along with the diagnosis, there is an increasing need to evaluate prognostic markers like CD10, BCL2, BCL6 and MUM1 to subcategorize DLBCL into Germinal Centre (GC) type or Activated B Cell (ABC) type as they have different survival rates.
Microscopically, the thyroid gland was infiltrated by a diffuse proliferation of atypical, large lymphoid cells Integrated histological and immunohistochemical analyses led to the diagnosis of diffuse large B-cell lymphoma (DLBCL) with a high proliferation index (Ki-67: 80%) and positive CD20 and BCL6 (Figure 1).
The researchers found that the gene - known in scientific shorthand as BCL6 - can inhibit one of the pathways cells use to transmit signals to other cells.
Project proposal: Targeted Inhibition of BCL6 for Leukemia Stem Cell Eradication
Apart from CD10, BCL2, BCL6 and Ki-67 immunostains, CD38 and CD44 are often helpful for this distinction [17].
Immunohistochemistry demonstrated CD20 reactivity and lack of CD5, cyclin D1, CD23 and BCL6 expression by the population of lymphoid cells, indicating B-cell lineage and supported the diagnosis of MALT lymphoma.
Now a team of scientists led by researchers at Children's Hospital Los Angeles and the University of California San Francisco (UCSF) have identified the reason for this drug resistance: BCL6, a protein that leukemia cells use to stay alive in spite of chemotherapy.
The MUM-1 positivity and the CD10 and BCL6 negativity indicate that this lymphoma was of postgerminal center origin (activated B-cell type).
Muschen's presentation is "Targeting BCL6 in acute lymphoblastic leukemia" (April 7, 2:15 p.
Similar to BL in immunocompetent patients, HIV-related BLs are positive for pan-B-cell antigens, CD10, and BCL6 but are negative for BCL2.